Psilocybin for Veterans with PTSD: What Research Shows in 2026
Veterans represent one of the populations most urgently in need of better PTSD treatments. Current treatments — prolonged exposure therapy, cognitive processing therapy, SSRIs — help many veterans but leave a significant proportion with persistent symptoms, high dropout rates from therapy, and elevated rates of suicide. The 2025 executive order directing the VA to study psychedelic medicine for veterans accelerated what was already a growing research focus.
The Research Foundation
The primary evidence base for psilocybin in PTSD-adjacent conditions comes from two areas:
MDMA-PTSD research (MAPS): While not psilocybin, the MAPS MDMA Phase 3 trials for PTSD showed striking results (67% no longer meeting PTSD criteria after three sessions) and directly demonstrated the viability of psychedelic-assisted therapy for this population. The MDMA results created a framework and political will that benefits psilocybin research.
Psilocybin and moral injury: NYU is conducting a trial specifically examining psilocybin for moral injury in veterans — a related but distinct condition characterized by guilt, shame, and ethical distress from combat actions, rather than the fear-based traumatic stress that defines classic PTSD. Early data from this trial was presented in 2024-2025 and showed promising signals.
General psilocybin depression/anxiety data: Veterans with PTSD have extremely high rates of comorbid depression and anxiety. The robust data from Hopkins and NYU on psilocybin for depression and the MDMA data on PTSD together build a strong rationale for psilocybin-specific PTSD trials.
The 2025 Executive Order
President Trump's January 2025 executive order directed the Department of Veterans Affairs (VA) and Department of Defense (DoD) to conduct research into psychedelic-assisted therapy for veterans. Specifically:
- VA and DoD were directed to evaluate existing research and identify gaps
- New VA-sponsored clinical trials of psilocybin and MDMA for PTSD and TBI were to be designed and funded
- A reporting timeline was established for recommendations on clinical implementation
As of 2026, this has resulted in the VA's Office of Research and Development (ORD) formally funding psilocybin PTSD trial protocols and identifying VA sites for expanded psychedelic research.
Current Active Trials (2026)
VA Palo Alto Health Care System / Stanford: Phase 2 trial of psilocybin-assisted therapy for combat veterans with PTSD and comorbid depression.
NYU Langone — Moral Injury Study: Examining psilocybin's specific effects on moral injury, guilt, and shame in veterans and first responders.
MAPS — MDMA Phase 3 extension: Additional MDMA PTSD research continues across VA-affiliated sites.
Several other VA sites are in the process of establishing research programs under the executive order mandate.
Access Outside of Clinical Trials
For veterans who cannot or do not want to wait for clinical trials:
Oregon Measure 109: Any adult 21+ can access Oregon's licensed psilocybin service centers. Veterans can attend as clients. Facilitators with military/trauma backgrounds are increasingly available.
Colorado Proposition 122: Similar legal access framework, with healing centers operational as of 2025-2026.
International access: Some veterans' organizations have facilitated or funded trips to legal psychedelic programs in Jamaica, Netherlands, and Mexico for combat veterans. There are nonprofit organizations specifically focused on psychedelic access for veterans.
Underground access: A significant proportion of veterans who have tried psilocybin have done so outside legal frameworks, typically through peer referral networks within veteran communities. The VA does not recommend this; harm reduction resources are still appropriate for these individuals.
The Evidence Gap and What's Coming
The honest state of the evidence for psilocybin specifically for combat-related PTSD: insufficient completed RCT data as of 2026. The mechanistic rationale is strong, the adjacent evidence (MDMA, general psilocybin) is compelling, and the executive order has accelerated formal research. Results from VA-sponsored trials are expected in 2026-2027.
The veteran community and their advocates are not waiting — demand for psychedelic-assisted therapy among veterans is high, and many are accessing it through legal (Oregon, Colorado) or informal channels while formal research catches up.
Resources for Veterans
- Heroic Hearts Project (heroichearts.org): Nonprofit connecting veterans with legal, supervised psychedelic experiences internationally
- VETS Inc. (vets.solutions): Veteran-focused psychedelic integration and research organization
- VA Crisis Line: 988, then press 1 — available 24/7 for veterans in crisis
- Fireside Project (62-FIRESIDE): Free peer support for psychedelic experiences